Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.

Denham JW, Steigler A, Lamb DS, Joseph D, Mameghan H, Turner S, Matthews J, Franklin I, Atkinson C, North J, Poulsen M, Christie D, Spry NA, Tai KH, Wynne C, Duchesne G, Kovacev O, D'Este C; Trans-Tasman Radiation Oncology Group.

Lancet Oncol. 2005 Nov;6(11):841-50.

PMID:
16257791
2.

Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.

Kumar S, Shelley M, Harrison C, Coles B, Wilt TJ, Mason MD.

Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006019. Review.

PMID:
17054269
4.

Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review.

Sasse AD, Sasse E, Carvalho AM, Macedo LT.

BMC Cancer. 2012 Feb 2;12:54. doi: 10.1186/1471-2407-12-54. Review.

5.

Short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer undergoing dose-escalated radiotherapy: the standard of care?

Zumsteg ZS, Zelefsky MJ.

Lancet Oncol. 2012 Jun;13(6):e259-69. doi: 10.1016/S1470-2045(12)70084-0. Review.

PMID:
22652234
6.

Hormone and radiotherapy versus hormone or radiotherapy alone for non-metastatic prostate cancer: a systematic review with meta-analyses.

Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N.

Clin Oncol (R Coll Radiol). 2014 Oct;26(10):e21-46. doi: 10.1016/j.clon.2014.06.016. Epub 2014 Jul 21. Review.

PMID:
25059922
7.

Synergistic action of image-guided radiotherapy and androgen deprivation therapy.

Locke JA, Dal Pra A, Supiot S, Warde P, Bristow RG.

Nat Rev Urol. 2015 Apr;12(4):193-204. doi: 10.1038/nrurol.2015.50. Epub 2015 Mar 24. Review.

PMID:
25800395
8.

Medical therapy of prostate cancer. A review.

Roscigno M, Sangalli M, Mazzoccoli B, Scattoni V, Da Pozzo L, Rigatti P.

Minerva Urol Nefrol. 2005 Jun;57(2):71-84. Review.

PMID:
15951731
10.

Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis.

Botrel TE, Clark O, dos Reis RB, Pompeo AC, Ferreira U, Sadi MV, Bretas FF.

BMC Urol. 2014 Jan 25;14:9. doi: 10.1186/1471-2490-14-9. Review.

11.

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk nonmetastatic prostate cancer: A systematic review and metaanalysis.

Leal F, Figueiredo MA, Sasse AD.

Int Braz J Urol. 2015 May-Jun;41(3):425-34. doi: 10.1590/S1677-5538.IBJU.2014.0412. Review.

12.

The role of radiotherapy in node-positive prostate cancer.

Baker BR, Mohiuddin JJ, Chen RC.

Oncology (Williston Park). 2015 Feb;29(2):108-14, 116. Review.

13.

Androgen deprivation therapy as primary treatment for prostate cancer.

Cannata DH, Kirschenbaum A, Levine AC.

J Clin Endocrinol Metab. 2012 Feb;97(2):360-5. doi: 10.1210/jc.2011-2353. Epub 2011 Dec 7. Review.

PMID:
22162475
14.

[Combined radiation therapy and androgen deprivation in the management of prostate cancer: Where do we stand?].

Bellefqih S, Hadadi K, Mezouri I, Maghous A, Marnouche E, Andaloussi K, Elmarjany M, Sifat H, Mansouri H, Benjaafar N.

Cancer Radiother. 2016 Apr;20(2):141-50. doi: 10.1016/j.canrad.2015.12.002. Epub 2016 Mar 8. Review. French.

PMID:
26969245
15.

Radiation-based approaches to the management of T3 prostate cancer.

Zietman AL, Westgeest JC, Shipley WU.

Semin Urol Oncol. 1997 Nov;15(4):230-8. Review.

PMID:
9421450
16.

Treatment options in locally advanced prostate cancer.

Swanson GP.

Minerva Urol Nefrol. 2007 Mar;59(1):27-42. Review.

PMID:
17431368
17.

Use of androgen deprivation therapy in prostate cancer: indications and prevalence.

Connolly RM, Carducci MA, Antonarakis ES.

Asian J Androl. 2012 Mar;14(2):177-86. doi: 10.1038/aja.2011.103. Epub 2012 Jan 9. Review.

18.

Prostate cancer.

Damber JE, Aus G.

Lancet. 2008 May 17;371(9625):1710-21. doi: 10.1016/S0140-6736(08)60729-1. Review.

PMID:
18486743
19.

Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer.

Thoms J, Goda JS, Zlotta AR, Fleshner NE, van der Kwast TH, Supiot S, Warde P, Bristow RG.

Nat Rev Clin Oncol. 2011 Feb;8(2):107-13. doi: 10.1038/nrclinonc.2010.207. Epub 2010 Dec 21. Review.

PMID:
21178999
20.

Fast neutrons in prostatic adenocarcinomas: worldwide clinical experience.

Lindsley KL, Cho P, Stelzer KJ, Koh WJ, Austin-Seymour M, Russell KJ, Laramore GE, Griffin TW.

Recent Results Cancer Res. 1998;150:125-36. Review.

PMID:
9670287

Supplemental Content

Support Center